Jose M. Borrel
Research Subjects
Research Interests
Jose M. Borrel has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Andre Strydom
Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
1 shared publication - Anke Hüls
Emory University
1 shared publication - Coral Manso
Down España, 28001 Madrid, Spain
1 shared publication - Diego Real de Asúa
Department of Internal Medicine, Instituto de Investigación Sanitaria (IIS Princesa), Hospital Universitario La Princesa, Madrid, Spain
1 shared publication - Domingo González-Lamuño
Departamento de Ciencias Médicas y Quirúrgicas. Facultad de Medicina. Universidad de Cantabria. Santander. España. / Servicio de Pediatría. Hospital Universitario Marqués de Valdecilla. Instituto de Investigación Marqués de Valdecilla (IDIVAL). Santander. España
1 shared publication - Fernando Moldenhauer
Adult Down Syndrome Outpatient Clinic, Department of Internal Medicine, Instituto de Investigación Sanitaria-Princesa (IIS-IP), Hospital Universitario de La Princesa, Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 23 August 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (16) , 3748
Comparison of COVID-19 and Non-COVID-19 Pneumonia in Down Syndrome
Whether the increased risk for coronavirus disease 2019 (COVID-19) hospitalization and death observed in Down syndrome (DS) are disease specific or also occur in individuals with DS and non-COVID-19 pneumonias is unknown. This retrospective cohort study compared COVID-19 cases in persons with DS hospitalized in Spain reported to the Trisomy 21 Research Society COVID-19 survey (n = 86) with admissions for non-COVID-19 pneumonias from a retrospective clinical database of the Spanish Ministry of Health (n = 2832 patients). In-hospital mortality rates were significantly higher for COVID-19 patients (26.7% vs. 9.4%), especially among individuals over 40 and patients with obesity, dementia, and/or epilepsy. The mean length of stay of deceased patients with COVID-19 was significantly shorter than in those with non-COVID-19 pneumonias. The rate of admission to an ICU in patients with DS and COVID-19 (4.3%) was significantly lower than that reported for the general population with COVID-19. Our findings confirm that acute SARS-CoV-2 infection leads to higher mortality than non-COVID-19 pneumonias in individuals with DS, especially among adults over 40 and those with specific comorbidities. However, differences in access to respiratory support might also account for some of the heightened mortality of individuals with DS with COVID-19.
- 23 August 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (16) , 3748
Open AccessComparison of COVID-19 and Non-COVID-19 Pneumonia in Down Syndrome
Whether the increased risk for coronavirus disease 2019 (COVID-19) hospitalization and death observed in Down syndrome (DS) are disease specific or also occur in individuals with DS and non-COVID-19 pneumonias is unknown. This retrospective cohort study compared COVID-19 cases in persons with DS hospitalized in Spain reported to the Trisomy 21 Research Society COVID-19 survey (n = 86) with admissions for non-COVID-19 pneumonias from a retrospective clinical database of the Spanish Ministry of Health (n = 2832 patients). In-hospital mortality rates were significantly higher for COVID-19 patients (26.7% vs. 9.4%), especially among individuals over 40 and patients with obesity, dementia, and/or epilepsy. The mean length of stay of deceased patients with COVID-19 was significantly shorter than in those with non-COVID-19 pneumonias. The rate of admission to an ICU in patients with DS and COVID-19 (4.3%) was significantly lower than that reported for the general population with COVID-19. Our findings confirm that acute SARS-CoV-2 infection leads to higher mortality than non-COVID-19 pneumonias in individuals with DS, especially among adults over 40 and those with specific comorbidities. However, differences in access to respiratory support might also account for some of the heightened mortality of individuals with DS with COVID-19.